1. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J. Clin. Oncol.,2012
2. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011
3. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model;Byrne;Clin. Cancer Res.,2003
4. Development of yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem;Cuevas;Nat. Prod. Rep.,2009